13 results about "Viral Inactivation" patented technology

The invention relates to the technical field of biological medicines, in particular to a soluble skin-adhering microneedle for delivering an inactivated enterovirus vaccine as well as a preparation method and application of the soluble skin-adhering microneedle. Sodium hyaluronate is adopted as a film forming material to wrap an enterovirus 71 type (EV71)-coxsackie virus A16 (CA16) type bivalent inactivated vaccine antigen, and a needle body layer of the soluble microneedle is formed; the substrate layer is prepared from a pullulan material, so that the microneedle patch with a stable overall structure is formed. The technology provided by the invention is completed in a clean environment, and the vaccine patch which is qualified through sterility detection is obtained. The soluble microneedle disclosed by the invention has good antigen stability under the condition of 2-8 DEG C. In animal experiments, the microneedle is attached to the skin surface of a mouse for skin-adhering immunization, a strong immune response reaction can be induced, good immunogenicity is shown, and a novel, safe and effective vaccine delivery way is provided for prevention and control of the infantile hand-foot-and-mouth disease.

The application discloses a natural recombination novel duck reovirus variant (NDRV-GXNN-2025) strain, which has a preservation number of CCTCC No:V202613 and a preservation date of January 28, 2026. Researches show that the NDRV-GXNN-2025 strain has high pathogenicity to ducklings and goslings, and the mortality rates of 2-day-old ducklings and goslings are 30% and 50% respectively when the attack dose is 104.0 / 0.1ml; meanwhile, the strain has good immunogenicity and is an ideal vaccine candidate strain. Accordingly, the inventors also establish a preparation method of a corresponding inactivated vaccine. The novel duck reovirus inactivated vaccine prepared by the method has good stability and safety, can induce the body to produce high-level neutralizing antibodies after immunizing ducklings and goslings, and can effectively resist the attack of the novel duck reovirus variant, and has a good application prospect.

The present invention provides intravenous pharmaceutical compositions comprising engineered plant virus-based nanoparticles for the treatment or prevention of autoimmune conditions. The nanoparticles display immunodominant peptides that induce immune tolerance in a subject when administered intravenously. The invention further provides methods of manufacturing virus-based nanoparticles, including production in plant expression systems and optional viral inactivation, to render them suitable for therapeutic use in mammals. Also provided are methods of intravenous administration of the pharmaceutical compositions to a subject in need thereof for treating or preventing autoimmune conditions.

The invention relates to a non-guanidine salt type compatible nucleic acid extraction virus preservation solution as well as a preparation method and application thereof, and the virus preservation solution comprises P (HEMA-BAMPD hydrochloride), a buffer agent, a chelating agent, a saccharide stabilizer and an osmotic pressure regulator. The P (HEMA-BAMPD hydrochloride) is used for replacing guanidine salt and small molecule quaternary ammonium salt, the inactivation rate effect on enveloped RNA / DNA viruses such as SARS-CoV-2 viruses and influenza viruses is good, no irritation is generated, and the method is friendly to operators and the environment; the macromolecular structure realizes multi-point adsorption and has strong organic matter interference resistance, and a small amount of blood, sputum and other components in the sample do not influence the inactivation effect. Moreover, the P (HEMA-BAMPD hydrochloride), the chelating agent and the saccharide stabilizer have a synergistic effect, so that the activities of RNase and DNase can be effectively inhibited.

The invention belongs to the technical field of aquatic immunity and biological preparations, and discloses a CXCL20a protein mutant and application of the CXCL20a protein mutant as a grass carp reovirus inactivated vaccine adjuvant. In order to improve the immunomodulatory activity of CXCL20a, the applicant constructs and obtains a CXCL20a mutant protein. After the mutant and a GCRV-II type inactivated vaccine are combined to immunize grass carp, the expression of immune related genes can be remarkably promoted, the activity of serum acid phosphatase and superoxide dismutase is enhanced, and meanwhile, the level of lactic dehydrogenase is reduced. A challenge experiment proves that the survival rate of the grass carp combined with the inactivated vaccine for immunization is increased by about 8% compared with that of a non-mutant combined group, and the in-vivo virus load is reduced. As an immunologic adjuvant, the CXCL20a mutant M-C20 provided by the invention can effectively enhance early immune response and overall protection effect in vaccine immunity, and has good safety, stability and application prospect.

The application discloses a preparation method and application of a Seneca Valley Virus disease inactivated vaccine for pigs, and the vaccine is prepared by using the following steps: suspending culture of Seneca Valley Virus, chromatographic purification of an antigen, and preparation of the vaccine by using an optimized water adjuvant. The Seneca Valley Virus inactivated vaccine prepared by the method has good safety, can induce piglets to generate high-level neutralizing antibodies, and effectively protects a pig group from the attack of a Seneca Valley Virus virulent virus for pigs.

This invention discloses a data-driven modeling and predictive control method for respiratory virus inactivation, relating to the field of biomedical technology. The method includes the following steps: obtaining initial viral characteristic data from a viral surface structure database through molecular dynamics simulation, processing the data to obtain a structural change matrix of the virus under different inactivation conditions; using a support vector machine classifier based on the structural change matrix to extract features of viral characteristics and antibody binding sites, determining a set of potential unexpected interaction sites. This data-driven modeling and predictive control method for respiratory virus inactivation effectively improves the scientific validity and stability of inactivation process parameters, reduces safety risks caused by improper inactivation conditions, shortens the process optimization cycle, reduces experimental costs, and helps maintain good immunogenicity while ensuring the safety of virus inactivation, thereby better meeting the practical application needs in vaccine development and virus prevention and control.

The invention provides a recombinant rabies virus capable of simultaneously expressing a canine distemper virus H protein and a canine parvovirus VP2 protein between a G gene and an L gene, the recombinant rabies virus has better genetic stability and replication ability, and after the virus is inactivated, mice are immunized, so that the mice can simultaneously generate neutralizing antibodies for resisting RABV, CDV and CPV.

The present application relates to a kind of non-guanidine salt type compatible nucleic acid extraction virus preservative and preparation method and application, the virus preservative, including P (HEMA-BAMPD) hydrochloride, buffer, chelating agent, saccharide stabilizer and osmotic pressure regulator.The present application replaces guanidine salt and small molecule quaternary ammonium salt with P (HEMA-BAMPD) hydrochloride, and the inactivation rate effect of SARS-CoV-2 virus, influenza virus and other envelope type RNA / DNA viruses is good, and there is no irritability, and it is friendly to operating personnel and environment;Polymer structure realizes multiple point adsorption, and the ability of resistance to organic interference is strong, and a small amount of blood, sputum and other components in sample do not affect inactivation effect.Moreover, P (HEMA-BAMPD) hydrochloride, chelating agent and saccharide stabilizer synergistic effect can effectively inhibit RNase, DNase activity.

A culture chamber that can be provided in a modular form to provide flexibility in the flow rate and / or residence time of a product stream is disclosed. An assembly comprising such a culture chamber for the purification of biomolecules is also disclosed, as well as a method for the purification of biomolecules, and in particular a method for inactivating viruses in a culture chamber or a plurality of culture chambers arranged in series.

The application provides an application of trichostatin A in promoting RNA virus proliferation, and belongs to the field of chemical medicines.The application discloses a new application of trichostatin A in promoting RNA virus proliferation, and trichostatin A can effectively promote the-1 Ribosomal Frameshifting process of the RNA virus, can effectively promote the replication and proliferation of the RNA virus, can be used for preparing a product for promoting the proliferation of the RNA virus, and can be used for producing and preparing an RNA virus inactivated vaccine or attenuated vaccine, can effectively reduce production cost and shorten a production cycle, and has wide application prospect and economic value.

An improved technology for inactivation of viruses, for example the SARS-COV-2 virus that is causing the Covid-19 pandemic, is described. The technology can include a device that includes a substrate coated in a polymer that is infused with a pathogen inactivating material. In various embodiments, at a given time, a portion of the pathogen inactivating material is exposed to the environment, and the device is configured to periodically or intermittently expose additional pathogen inactivating material to the environment. For example, the polymer can be ablative or sacrificial.

The virus inactivation compound according to the present invention is a compound represented by formula (1) or formula (2). (In formula (1), n is an integer of 3-19, and in formula (2), m is an integer of 3-19). The present invention makes it possible to provide a virus inactivation compound having an excellent virus inactivation effect.